Deregulation of two major signalling pathways, the RAS-RAF-MEK-ERK and PI3K-AKT-PTEN, are key drivers of melanoma development and progression [1], with ~50% and ~25% of patients expressing constitutively active mutants of MAP-kinases BRAF and NRAS, respectively [2]. This evidence concerns the gene NRAS and melanoma.